PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-8.17%
R&D reduction while Healthcare median is 0.00%. Seth Klarman would investigate competitive implications.
28.86%
G&A change of 28.86% versus flat Healthcare overhead. Walter Schloss would verify efficiency.
No Data
No Data available this quarter, please select a different quarter.
-40.21%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
6.04%
Operating expenses growth near Healthcare median of 5.74%. Charlie Munger would verify industry norms.
6.04%
Total costs growth near Healthcare median of 5.51%. Charlie Munger would verify industry norms.
-100.00%
Interest expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-40.21%
D&A reduction while Healthcare median is 0.00%. Seth Klarman would investigate efficiency.
-66.22%
EBITDA decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-6.04%
Operating income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-333.64%
Other expenses reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-65.74%
Pre-tax income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Tax expense reduction while Healthcare median is 0.00%. Seth Klarman would investigate advantages.
-65.74%
Net income decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-47.67%
EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
-53.82%
Diluted EPS decline while Healthcare median is 0.00%. Seth Klarman would investigate causes.
12.14%
Share count change of 12.14% versus stable Healthcare. Walter Schloss would verify approach.
7.50%
Diluted share change of 7.50% versus stable Healthcare. Walter Schloss would verify approach.